Abstract
Background: Coronavirus disease 2019 (COVID-19) has spread almost all regions of the world and caused great loss to the whole body of mankind. Thus, numerous clinical trials were conducted to find specific medicine for COVID-19 recently. However, it remains unanswered whether they are beneficial.
Objective: This study aimed to evaluate the efficiency and safety of the COVID-19 medicine.
Methods: Studies were determined through searching PubMed, Embase, Cochrane Library, and Medline. The studies of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement, and rate of serious adverse events.
Results: A total of 33 studies involving 37,879 patients were included in our study, whose intervening measures contained three major types of COVID-19 medicine, ACEI/ARB, antiviral medicine, and chloroquine/hydroxychloroquine. Compared to control group, COVID-19 drugs have no distinct effect on mortality (RR, 0.93; 95% CI, 0.79-1.11, P = .43) and discharge rate (RR, 1.06; 95% CI, 0.98-1.14, P = .13). However, antiviral medicine presents the obvious advantage in clinical improvement (RR, 1.11; 95% CI, 1.01-1.23, P < .05). In addition, the serious adverse events rate (RR, 0.75; 95% CI, 0.63-0.88, P < .05) of COVID-19 medicine is lower than control group.
Conclusion: The results indicated antiviral medicine was potential specific medicine for COVID-19 treatment by improving clinical symptoms, but it failed to increase the discharge rate and reduce mortality. Chloroquine/hydroxychloroquine and ACEI/ARB had no significant effect on treatment of COVID-19, thus they were not recommended for routine medication. Moreover, more trials are needed to find effective drugs to lower the mortality of COVID-19 patients.
【초록키워드】 COVID-19, Treatment, coronavirus disease, Coronavirus disease 2019, clinical trial, Chloroquine, Mortality, Trial, Hydroxychloroquine, Clinical symptoms, drug, effective drugs, COVID-19 treatment, Spread, Region, Patient, Clinical improvement, medication, COVID-19 patients, ACEi, Efficiency, chloroquine/hydroxychloroquine, Serious Adverse Events, Serious Adverse Event, whole body, control group, 95% CI, no significant effect, significant effect, Cochrane Library, measure, end point, discharge rate, ACEi/ARB, antiviral medicine, reduce mortality, evaluate, caused, involved, indicated, addition, conducted, had no, effective drug, eligible, 【제목키워드】 Meta-analysis, systematic review, drug, therapeutic effect,